Skip to content

Released Mar 18, 2026, before the open

10-K filed Mar 18, 2026, 77 days after period end · 0001104659-26-029858

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$9.12Mderived−49.9% vs Q4 2024−48.9% vs Q3 2025
Net Income-$5.50MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$4,658,000N/M
Operating Cash Flowderived$2,030,000−49.1%
Free Cash Flowderived$1,627,000−54.4%
Margins · derived
Operating margin-51.1%−90.6 pt vs Q4 2024
Net margin-60.3%−96.0 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$9.12M$18.22M$10.49M$8.62M
Net Income-$5.50M$6.49M-$6.04M-$3.74M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR